Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
R3H domain-containing protein 1 (R3HDM1) is a ubiquitously expressed, primarily nuclear protein encoded by the human R3HDM1 gene located on chromosome 2[4][9]. It contains an R3H domain, a conserved motif known to mediate binding to single-stranded nucleic acids, particularly RNA[7][11]. R3HDM1 is functionally annotated as an RNA-binding protein, implicated in the regulation of gene expression through interaction with RNA molecules[1][5][11]. Diseases associated with R3HDM1 variants include centronuclear myopathy with fiber-type disproportion and pulmonary embolism, but evidence for a direct or druggable disease-driving role is limited at this time[5]. There are currently no approved drugs or clinical candidates reported to target R3HDM1, nor is it established as a validated therapeutic target or clinical biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on R3H domain-containing protein 1 (R3HDM1).